MEDC Staff
Thursday, January 24, 2019
Those in the genomic space likely understand that interpreting next-generation sequencing of DNA data can be frustratingly inefficient and error prone. Fortunately, there's an answer!
Enter, Genomenon—a genomic interpretation software used for clinical diagnostics in cancer and genetic diseases—that spun out of the University of Michigan in 2014 by co-founders Mark Kiel and Steve Schwartz. Genomenon was an early MEDC Michigan Translational Research and Commercialization (MTRAC) project in U-M’s Life Sciences Program. Having received additional support through Phase I and II Emerging Technologies Fund awards from Michigan’s Small Business Development Center, Genomenon reduces the time pathologists and geneticists spend researching and interpreting genetic variants from hours to minutes (!).
Mike Klein—a serial entrepreneur with over 25 years of developing, building and growing high-tech and software companies—joined Genomenon as CEO in 2016 to help launch the company’s first product: Mastermind, a gene-variant knowledgebase built on mining millions of medical publications. This product significantly shortens the time it takes to search through medical literature for disease-causing variants by automatically sorting through the extensive genomic literature.
If you’ve got a high-tech start-up idea you’d like to explore further and don’t know where to start, contact the Michigan Economic Development Corporation’s Entrepreneurship & Innovation initiative at 888-522-0103 or visit https://www.michiganbusiness.org/entrepreneurship.
Contact Us
To contact a business development specialist, click here or call 1.888.522.0103.
